Haemonetics Appoints New CFO, Restructures Key Roles

Ticker: HAE · Form: 8-K · Filed: Sep 16, 2024 · CIK: 313143

Haemonetics Corp 8-K Filing Summary
FieldDetail
CompanyHaemonetics Corp (HAE)
Form Type8-K
Filed DateSep 16, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: executive-change, personnel

TL;DR

Haemonetics names new CFO, Brian J. Smith, effective Sept 16. Brenda Foster moves to Strategic Initiatives.

AI Summary

Haemonetics Corp. announced on September 10, 2024, changes in its executive team. The company appointed Brian J. Smith as Chief Financial Officer and Executive Vice President, effective September 16, 2024. Concurrently, Brenda L. Foster will transition from CFO to Executive Vice President, Strategic Initiatives, and will also serve as interim General Counsel.

Why It Matters

This executive reshuffling signals a strategic shift within Haemonetics, potentially impacting financial strategy and legal oversight.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially the CFO, can introduce uncertainty regarding future financial strategies and operational execution.

Key Players & Entities

  • Haemonetics Corp. (company) — Registrant
  • Brian J. Smith (person) — Appointed Chief Financial Officer and Executive Vice President
  • Brenda L. Foster (person) — Transitioning from CFO to Executive Vice President, Strategic Initiatives and interim General Counsel
  • September 10, 2024 (date) — Date of Report
  • September 16, 2024 (date) — Effective date for new CFO

FAQ

What is the effective date for Brian J. Smith's appointment as CFO?

Brian J. Smith's appointment as Chief Financial Officer and Executive Vice President is effective September 16, 2024.

What new role will Brenda L. Foster assume?

Brenda L. Foster will transition from CFO to Executive Vice President, Strategic Initiatives, and will also serve as interim General Counsel.

What is Haemonetics Corporation's state of incorporation?

Haemonetics Corporation is incorporated in Massachusetts.

What is the company's principal executive office address?

The principal executive offices are located at 125 Summer Street, Boston, MA 02110.

What is the SIC code for Haemonetics Corp.?

The Standard Industrial Classification (SIC) code for Haemonetics Corp. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

Filing Stats: 426 words · 2 min read · ~1 pages · Grade level 11.9 · Accepted 2024-09-16 16:17:28

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION September 16, 2024 By: /s/ Christopher A. Simon Name: Christopher A. Simon Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.